Lawsuit against Humana moves forward over alleged false statements on healthcare costs.

A securities fraud lawsuit against Humana and its former CEO and CFO will proceed after a judge ruled key claims valid. The lawsuit alleges that from July 2022 to October 2024, Humana misled investors about increased healthcare utilization costs, causing its stock price to be artificially inflated. Company insiders sold over $104 million in stock during this period. The case highlights potential wrongdoing by Humana's directors and officers, and shareholders may have legal options.